Physician profile
Ando Muneno
NPI 1164977005
$1,570.80
in general payments reported to CMS, 2019-2025
13 companies · $85.04 in 2025
The $85.04 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $358 · 2023: $62.20 · 2024: $465 · 2025: $85.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $693.42 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Abbvie INC. | $270.25 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $122.42 | 2021-2024 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $92.02 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $67.21 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $60.66 | 2021-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $53.59 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.37 | 2024 | Caplyta |
| Alkermes, INC. | $42.84 | 2021-2024 | Vivitrol |
| Bausch Health US, LLC | $36.72 | 2024 | Aplenzin |
| Indivior INC. | $36.19 | 2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $27.55 | 2024 | Uzedy |
| Boston Scientific Corporation | $16.56 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ando Muneno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.